Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
DJ Dhasmana, PW Horby, MJ Landray… - The …, 2022 - research-repository.st-andrews.ac …
Background: Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
DJ Dhasmana, PW Horby, MJ Landray… - The …, 2022 - research-portal.st-andrews.ac.uk
Background: Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …